BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Business

  AstraZeneca Returns to FibroGen the Rights to Roxadustat in US, Other Territories

  More than two years after an FDA rejection, AstraZeneca has given back to FibroGen U.S. and rest-of-world rights to the HIF-PH inhibitor, though the companies will maintain their contract in China and South Korea.

  February 28, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  Theratechnologies’ HIV Therapy Trogarzo Denied FDA Review

  The Canadian biotech’s regulatory setbacks continued on Tuesday with an FDA Refusal to File letter for its intramuscular formulation of the humanized monoclonal antibody Trogarzo.

  February 28, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Pilot Study Shows Better eConsents Create Better Human Experiences

  Electronic consent can personalize the patient experience in clinical trials and even improve retention. At Medable, where I am CSO, we’re committed to driving the adoption of this transformative technology.

  February 28, 2024

   · 

  5 min read

   · 

  Pamela Tenaerts
• 

  Policy

  Stakeholders Hope Bill Will Create IRA Drug Negotiation Parity Between Biologics and Small Molecules

  Congressional legislation seeks to “equalize” the negotiating period between biologics and small molecules under the Inflation Reduction Act’s Drug Price Negotiation Program.

  February 28, 2024

   · 

  5 min read

   · 

  Greg Slabodkin
• 

  Business

  C-Suite Shuffle: ReNAgade, Adaptimmune, Vittoria and More

  Plus, last week Richard Gonzalez announced his retirement from AbbVie, PhRMA appointed Gilead’s O’Day to chair its board and Joseph Papa became president and CEO of Emergent.

  February 28, 2024

   · 

  5 min read

   · 

  Neil Versel
• 

  Business

  Viatris, Idorsia Ink $350M R&D Pact for Two Phase III Assets

  Under the research and development agreement announced Wednesday, Viatris is securing global rights to Idorsia’s late-stage heart and lupus candidates.

  February 28, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Rare Disease Drug Development Urgently Needs More Funding, Experts Say

  Despite recent investment and breakthroughs for rare diseases such as Friedreich’s ataxia and progeria, experts say helping patients with rare diseases will require cross-sector support.

  February 28, 2024

   · 

  6 min read

   · 

  Nadia Bey
• 

  Business

  AbbVie Puts Potential $713M on the Line for OSE’s Inflammation Antibody

  AbbVie continued its dealmaking spree Wednesday by partnering with OSE Immunotherapeutics to develop its early-stage, first-in-class antibody for chronic and severe inflammation.

  February 28, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Novavax Q4 Revenue and Earnings Miss Estimates, Stock Drops Over 25%

  The vaccine maker’s fourth-quarter revenue and earnings on Wednesday missed Wall Street expectations, while providing full-year 2024 sales guidance of flat to lower than last year.

  February 28, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Genetown

  9 Companies Hiring in the Genetown Hotbed

  If you’re a life sciences professional in the Genetown hotbed (Boston, Cambridge and the surrounding areas of Massachusetts) and are looking for your next challenge, take a look at these companies hiring on BioSpace.

  February 28, 2024

   · 

  1 min read

   · 

  BioSpace Editorial Staff